Cardiogenic Shock - Cardiogenic Shock - 514 · cardiogenic-shock
    • CardiologyTalk

      Site: CardiologyTalk

    • Quick Links
      • Schedule An Interview
      • What Is Our Interview Process
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Hungarian (Hungary)
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • Home
  • Trending

  • Login

  • Audio and Video
  • Videos
  • Audio

  • Channels
  • Browse Channels

  • Categories
  • Acute Pulmonary Embolism 1
  • Amyloidosis 10
  • Angina 1
  • Anticoagulation Management 1
  • Aortic Stenosis 1
  • Arrhythmias and Clinical EP 2
  • Atrial Fibrillation 18
  • Autonomic Cardiology 1
  • Blood Pressure 1
  • Cardiac Implantable Electronic Devices 2
  • Cardiac Injury 3
  • Cardiac Surgery 13
  • Cardio-Oncology 17
  • Cardiogenic Shock 4
  • Cardiology 111
  • Cardiology Advocacy 16
  • Cardiomyopathy 5
  • Cardiorenal 2
  • Cardiorenal Syndrome 1
  • Cardiovascular Disease 17
  • Cardiovascular Imaging 2
  • Conference Coverage 63
  • Congenital Heart Disease 1
  • Coronary Artery Disease 11
  • Coronary Microvascular Dysfunction 3
  • Coronary Pharmacotherapy 1
  • Coronary Stent 2
  • COVID-19 81
  • Diabeto-Cardiology 2
  • Dyslipidemia 1
  • Echocardiograms 3
  • Heart Disease 1
  • Heart Failure and Cardiomyopathies 60
  • Heart Transplant 1
  • Heart Valve 3
  • Hemostasis 1
  • Hypertension 12
  • Hypertrophic Cardiomyopathy 2
  • Irregular Heart Rhythm 1
  • Ischemic Heart Disease 4
  • Myocardial Infarction 13
  • Prevention 4
  • Pulmonary Hypertension 2
  • Stroke 1
  • Structural Heart Disease 1
  • TAVR 3
  • Transcatheter Aortic Valve (TAVI) 3
  • Tricuspid Regurgitation 1
  • Valvular Heart Disease 2
  • Vasovagal Syncope 1
  • Ventricular Failure 1
  • Acute Coronary Syndromes 189

  • Install
  • Play a Link
  • About
  • Contact
Dr. Benjamin Hibbert - @benhibbertMDPhD @RebeccaMathewMD @Disantopietro @HeartInstitute #CardiogenicShock #Cardiology #Research  Milrinone as Compared with Dobutamine in the Treatment of... Dr. Benjamin Hibbert - @benhibbertMDPhD @RebeccaMathewMD @Disantopietro @HeartInstitute #CardiogenicShock #Cardiology #Research  Milrinone as Compared with Dobutamine in the Treatment of...
0:06:00

Dr. Benjamin Hibbert - @benhibbertMDPhD @RebeccaMathewMD ...

Dr. Benjamin Hibbert MD. University of Ottawa Heart Institute - Speaks on Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock

Link to Abstract:
https://www.nejm.org/doi/full/10.1056/NEJMoa2026845?query=cardiology


CONTEXT: Cardiogenic shock is linked to a high rate of morbidity and mortality. Although inotropic support is a common part of medical treatment for cardiogenic shock, there is no data to guide inotropic drug selection in clinical practice.

METHODS: In a double-blind study, individuals with cardiogenic shock were randomly randomized to receive milrinone or dobutamine. In-hospital death from any cause, resuscitated cardiac arrest, cardiac transplantation or mechanical circulatory support, nonfatal myocardial infarction, transient ischemic attack or stroke identified by a neurologist, or beginning of renal replacement therapy were the major outcomes. Individual components of the primary composite result were included as secondary outcomes.

RESULTS: A total of 192 people were enrolled (96 in each group). The primary result did not differ substantially between the treatment groups; 47 participants (49%) in the milrinone group and 52 participants (54%) in the dobutamine group (relative risk, 0.90; 95 percent confidence interval [CI], 0.69 to 1.19; P=0.47) experienced a primary outcome event. Secondary outcomes such as in-hospital death (37 percent and 43 percent of participants, respectively; relative risk, 0.85; 95 percent CI, 0.60 to 1.21), resuscitated cardiac arrest (7 percent and 9 percent; hazard ratio, 0.78; 95 percent CI, 0.29 to 2.07), and mechanical circulatory support (12 percent) showed no significant differences between the groups (22 percent and 17 percent ; hazard ratio, 1.39; 95 percent CI, 0.73 to 2.67).

CONCLUSIONS: There was no significant difference between milrinone and dobutamine in individuals with cardiogenic shock in terms of the key composite outcome or crucial secondary outcomes. (Funded by the Ontario Academic Health Sciences Centres Alternative Funding Plan's Innovation Fund; ClinicalTrials.gov number: NCT03207165. opens in new tab.)

32 Views
1 year Ago
Cardiology News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

Cardiogenic Shock Description
Cardiogenic Shock

Podcast - Dr. Benjamin Hibbert - @benhibbertMDPhD @RebeccaMathewMD @Disantopietro @HeartInstitute #CardiogenicShock #Cardiology #Research  Milrinone as Compared with Dobutamine in the Tre...
0:06:00
Podcast - Dr. Benjamin Hibbert - @benhibbertMDPhD @Rebecc...
19 Views
1 year Ago
Cardiology News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
Dr. Benjamin Hibbert - @benhibbertMDPhD @RebeccaMathewMD @Disantopietro @HeartInstitute #CardiogenicShock #Cardiology #Research  Milrinone as Compared with Dobutamine in the Treatment of... Dr. Benjamin Hibbert - @benhibbertMDPhD @RebeccaMathewMD @Disantopietro @HeartInstitute #CardiogenicShock #Cardiology #Research  Milrinone as Compared with Dobutamine in the Treatment of...
0:06:00
Dr. Benjamin Hibbert - @benhibbertMDPhD @RebeccaMathewMD ...
FHD
32 Views
1 year Ago
Cardiology News
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
IABP Use in Cardiogenic Shock
00:56:36
IABP Use in Cardiogenic Shock
0 Views
1 year Ago
Yale Cardiovascular Medicine Grand Rounds
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login
#24 Cardiogenic Shock case discussion #24 Cardiogenic Shock case discussion
0:45:28
#24 Cardiogenic Shock case discussion
32 Views
2 years Ago
HeartSuccess
Add to
Want to watch this again later?
Sign in to add this video to a playlist. Login

CardiologyTalk Copyright 2020